Shaji Kumar, MD
Shaji K. Kumar, MD, is Consultant in the Division of Hematology and Mark and Judy Mullins Professor of Hematological Malignancies at Mayo Clinic in Rochester, Minnesota. He is the Chair of the Myeloma, Amyloidosis and Dysproteinemia Disease Group at Mayo Clinic.
Dr. Kumar received his medical degree from the All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in internal medicine from the All India Institute of Medical Sciences, followed by an internal medicine residency and a hematology/oncology fellowship at the Mayo Graduate School of Medicine in Rochester, Minnesota.
Dr. Kumar’s research focuses on the development of novel drugs and drug combinations for the treatment of myeloma. His laboratory focuses on understanding the role of bone marrow microenvironment in the development and progression of myeloma.
Dr. Kumar serves as Co-Chair of the NCI Myeloma Steering Committee as Chair of the NCCN Multiple Myeloma Guidelines Panel.
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, AntengeneDate added:09/22/2021
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen, Janssen, , Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio, Molecular TemplatesDate added:09/22/2021